{"doi":"10.1038/s41541-020-0174-9","title":"Efficacy of FLU-v, a broad-spectrum influenza vaccine, in a randomized phase IIb human influenza challenge study","abstract":"Abstract FLU-v, developed by PepTcell (SEEK), is a peptide vaccine aiming to provide a broadly protective cellular immune response against influenza A and B. A randomized, double-blind, placebo-controlled, single-center, phase IIb efficacy and safety trial was conducted. One hundred and fifty-three healthy individuals 18–55 years of age were randomized to receive one or two doses of adjuvanted FLU-v or adjuvanted placebo subcutaneously on days −43 and −22, prior to intranasal challenge on day 0 with the A/California/04/2009/H1N1 human influenza A challenge virus. The primary objective of the study was to identify a reduction in mild to moderate influenza disease (MMID) defined as the presence of viral shedding and clinical influenza symptoms. Single-dose adjuvanted FLU-v recipients ( n = 40) were significantly less likely to develop MMID after challenge vs placebo ( n = 42) (32.5% vs 54.8% p = 0.035). FLU-v should continue to be evaluated and cellular immunity explored further as a possible important correlate of protection against influenza.","journal":"npj Vaccines","year":2020,"id":56808,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":82,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9511,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":295526,"name":"Emma L. James","orcid":"0000-0002-4031-4210","position":1,"is_corresponding":false},{"id":295527,"name":"Ana M. Fernández","orcid":"0000-0001-5160-3854","position":2,"is_corresponding":false},{"id":295528,"name":"Victor Lopes","orcid":"0000-0003-2249-9562","position":3,"is_corresponding":false},{"id":295529,"name":"Luz Angela Rosas","orcid":"0000-0002-8743-7189","position":4,"is_corresponding":false},{"id":296900,"name":"Adriana Cervantes-Medina","orcid":null,"position":5,"is_corresponding":false},{"id":295530,"name":"Jason Cleath","orcid":"0000-0002-3521-6122","position":6,"is_corresponding":false},{"id":295531,"name":"Kristina R. Edwards","orcid":"0000-0002-2251-1448","position":7,"is_corresponding":false},{"id":296901,"name":"Dana Neitzey","orcid":null,"position":8,"is_corresponding":false},{"id":295532,"name":"Wenjuan Gu","orcid":"0000-0002-9549-1919","position":9,"is_corresponding":false},{"id":295533,"name":"Sally Hunsberger","orcid":"0000-0002-4251-5622","position":10,"is_corresponding":false},{"id":233147,"name":"Jeffery K. Taubenberger","orcid":"0000-0002-9694-7228","position":11,"is_corresponding":false},{"id":296902,"name":"Gregory Stoloff","orcid":null,"position":12,"is_corresponding":false},{"id":233146,"name":"Matthew J. Memoli","orcid":"0000-0001-6393-5178","position":13,"is_corresponding":false},{"id":295525,"name":"Olga Pleguezuelos","orcid":"0000-0002-7099-5002","position":0,"is_corresponding":true}],"reference_count":44,"raw_metadata":null,"created_at":"2026-07-18T21:06:09.605575Z","pmid":"32194999","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}